{"name":"Brian J Lipworth","slug":"brian-j-lipworth","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Fluticasone propionate 50 micrograms per actuation","genericName":"Fluticasone propionate 50 micrograms per actuation","slug":"fluticasone-propionate-50-micrograms-per-actuation","indication":"Other","status":"marketed"},{"name":"Oxymetazoline 0.05% w/v","genericName":"Oxymetazoline 0.05% w/v","slug":"oxymetazoline-0-05-w-v","indication":"Nasal congestion due to colds, allergies, or sinusitis","status":"marketed"},{"name":"oxymetazoline-fluticasone propionate","genericName":"oxymetazoline-fluticasone propionate","slug":"oxymetazoline-fluticasone-propionate","indication":"Nasal congestion and symptoms of allergic rhinitis","status":"marketed"},{"name":"placebo to levocetirizine","genericName":"placebo to levocetirizine","slug":"placebo-to-levocetirizine","indication":"Allergic rhinitis","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Seretide 250/placebo via Synchro-Breathe","genericName":"Seretide 250/placebo via Synchro-Breathe","slug":"seretide-250-placebo-via-synchro-breathe","indication":"Asthma maintenance therapy","status":"marketed"},{"name":"Budesonide/formoterol and tiotropium","genericName":"Budesonide/formoterol and tiotropium","slug":"budesonide-formoterol-and-tiotropium","indication":"Asthma maintenance therapy","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Placebo to Prazosin","genericName":"Placebo to Prazosin","slug":"placebo-to-prazosin","indication":"Hypertension","status":"marketed"}]}],"pipeline":[{"name":"Fluticasone propionate 50 micrograms per actuation","genericName":"Fluticasone propionate 50 micrograms per actuation","slug":"fluticasone-propionate-50-micrograms-per-actuation","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Seretide 250/placebo via Synchro-Breathe","genericName":"Seretide 250/placebo via Synchro-Breathe","slug":"seretide-250-placebo-via-synchro-breathe","phase":"marketed","mechanism":"Seretide combines fluticasone propionate (inhaled corticosteroid) and salmeterol (long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Budesonide/formoterol and tiotropium","genericName":"Budesonide/formoterol and tiotropium","slug":"budesonide-formoterol-and-tiotropium","phase":"marketed","mechanism":"This combination reduces airway inflammation and constriction by combining a corticosteroid with two bronchodilators that work through different pathways.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Oxymetazoline 0.05% w/v","genericName":"Oxymetazoline 0.05% w/v","slug":"oxymetazoline-0-05-w-v","phase":"marketed","mechanism":"Oxymetazoline is an alpha-1 adrenergic agonist that constricts blood vessels in the nasal mucosa, reducing nasal congestion.","indications":["Nasal congestion due to colds, allergies, or sinusitis","Temporary relief of nasal obstruction"],"catalyst":""},{"name":"Placebo to Prazosin","genericName":"Placebo to Prazosin","slug":"placebo-to-prazosin","phase":"marketed","mechanism":"Prazosin is an alpha-1 adrenergic receptor antagonist that blocks norepinephrine signaling to reduce blood pressure and improve urinary symptoms.","indications":["Hypertension","Benign prostatic hyperplasia (BPH)","PTSD-related nightmares (off-label)"],"catalyst":""},{"name":"oxymetazoline-fluticasone propionate","genericName":"oxymetazoline-fluticasone propionate","slug":"oxymetazoline-fluticasone-propionate","phase":"marketed","mechanism":"This combination nasal spray uses a decongestant to reduce nasal swelling and a corticosteroid to suppress inflammatory responses in the nasal passages.","indications":["Nasal congestion and symptoms of allergic rhinitis","Chronic rhinosinusitis with nasal obstruction"],"catalyst":""},{"name":"placebo to levocetirizine","genericName":"placebo to levocetirizine","slug":"placebo-to-levocetirizine","phase":"marketed","mechanism":"Levocetirizine is a selective H1-receptor antagonist that blocks histamine signaling to reduce allergic symptoms.","indications":["Allergic rhinitis","Chronic urticaria","Allergic conjunctivitis"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":7,"phaseCounts":{"marketed":7},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}